<DOC>
	<DOCNO>NCT01402037</DOCNO>
	<brief_summary>Increased glycemic variability propose independent predictor hypoglycemia diabetic patient . Likewise , episodes dysglycemia find predictive diabetes antibodypositive nondiabetic individual . We hypothesise in-depth observational study compare state-of-the-art measure functional beta cell mass glycemic variability specify relationship variable broad range residual function identify treatment goal functional beta cell mass reach future beta cell therapy trial order avoid frequent hypoglycemia patient dysglycemia risk group . The available expertise infrastructure ( see background ( inter ) national context ) place promoter present project unique position carry plan experiment support feasibility .</brief_summary>
	<brief_title>Beta Cell Function ( Pre ) Type 1 Diabetes</brief_title>
	<detailed_description>The establish clinical network develop dynamic function test biological marker provide u unique opportunity identify sufficiently large group high-risk first-degree relative ( &gt; 50 % risk diabetes ) proband type 1 diabetes recent-onset type 1 diabetic patient overall aim investigate correlation functional beta cell mass glycemic variability relation metabolic outcome order determine threshold residual function : 1. glucose tolerance start decline sharply relatives 2. risk deteriorate metabolic control ( severe ) hypoglycemic event strongly increase patient To effect : 1. measure follow two-year period 1. functional beta cell mass participant determine AUC C-peptide release - preferred outcome measure type 1 diabetes trial hyperglycemic clamp test 2. participant ' within- between-day glycemic variability determine seven point selfmonitoring blood glucose ( SMBG ) continuous glucose monitoring ( CGM ) 5 day precede clamp procedure 2. perform oral glucose tolerance test ( OGTTs ; relative ) , determine HbA1c level centrally ( relatives patient ) record insulin requirement hypoglycemic episode ( patient ) Our previous experiment document selected patient relative ( see workplan ) display large inter-individual difference functional beta cell mass ( range anywhere control value &lt; 10 % control ) allow study glycemic variability function residual cell function large range value . They also illustrate recruitment capacity clinical network acceptance rate compliance patient relatives clamp procedure high sufficient carry plan experiment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Type 1 diabetic patient : 1. aged 1239 year diagnosis 2. treated insulin le 4 week 3. optimally treat intensified insulin treatment : minimal three preprandial injection ultrarapidly act analog one even injection longacting insulin ( LantusÂ® , Sanofi Aventis ) 4. positive autoantibody insulin ( IAAsampled within first week insulin treatment ) , 65kDa glutamate decarboxylase ( GADA ) , IA2 protein ( IA2A ) and/or zinc transporter 8 ( ZnT8A ) Firstdegree relatives : 1. aged 1239 year inclusion 2. sibling offspring type 1 diabetic patient diagnose age 35 age 35 50 addition body mass index &lt; 28 kg/m2 initial insulin dose &gt; 0.25 U.kg 1.d1 3 . &gt; 50 % risk diabetes within 5 year indicated positivity least 2 diabetes antibody include IA2A and/or ZnT8A absence protective HLADQ genotype ( 6 ) pregnancy lactation woman use illicit drug overconsumption alcohol history drug alcohol abuse legally incapacitate , significant emotional problem time study , history psychiatric disorder receive antidepressant medication last 6 month treatment immune modulate diabetogenic medication ( corticosteroid ) history illness , opinion investigator , might confound result study pose additional risk subject patient treat Lantus insulin therapy .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>Prevention</keyword>
	<keyword>First degree relative</keyword>
	<keyword>High risk type 1 diabetes</keyword>
</DOC>